Indaptus Therapeutics Q3 profit beats estimates
I'm PortAI, I can summarize articles.
Indaptus Therapeutics reported a Q3 2025 EPS of -$2.98, beating analyst expectations of -$4.17. The company raised $2.3 million to strengthen its balance sheet, while R&D expenses increased due to Phase 1 study costs. Indaptus expects its current cash to support operations into Q1 2026 and is evaluating financing options. Trial enrollment is paused pending further efficacy evaluations. The average analyst recommendation is "buy," with a 12-month price target of $25.00, significantly above its recent closing price of $2.72.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments